Protalix Capital Stock from 2010 to 2024

PLX Stock

USD 1.69 0.01 0.60%

Protalix Biotherapeutics Capital Stock yearly trend continues to be fairly stable with very little volatility. Capital Stock will likely drop to about 49.5 K in 2024. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals

Capital Stock

First Reported

2010-12-31

Previous Quarter

73 K

Current Value

49.5 K

Quarterly Volatility

53.3 K

Credit Downgrade

Yuan Drop

Covid

Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.8 M, Selling General Administrative of 26.7 M or Other Operating Expenses of 31.5 M, as well as many indicators such as Price To Sales Ratio of 1.74, Dividend Yield of 0.0 or PTB Ratio of 3.4. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.

Check out the analysis of Protalix Biotherapeutics Correlation against competitors.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Latest Protalix Biotherapeutics' Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Protalix Biotherapeutics over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Protalix Biotherapeutics' Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.

Capital Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Capital Stock

Timeline

Protalix Capital Stock Regression Statistics

	Arithmetic Mean	106,964
	Geometric Mean	88,516
	Coefficient Of Variation	49.83
	Mean Deviation	49,243
	Median	148,000
	Standard Deviation	53,300
	Sample Variance	2.8B
	Range	133K
	R-Value	(0.79)
	Mean Square Error	1.2B
	R-Squared	0.62
	Significance	0.0005
	Slope	(9,367)
	Total Sum of Squares	39.8B

Protalix Capital Stock History

	2024	49.5 K
	2023	73 K
	2022	54 K
	2021	46 K
	2020	35 K
	2019	15 K

Other Fundumenentals of Protalix Biotherapeutics

Issuance Of Capital Stock

Protalix Biotherapeutics Capital Stock component correlations

	Total Assets	Net Debt	Net Receivables	Total Liab	Total Current Assets	Total Stockholder Equity	Retained Earnings	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt	Capital Surpluse	Short Long Term Debt	Long Term Debt Total	Net Invested Capital	Cash And Equivalents	Net Working Capital	Capital Stock
Total Assets		-0.24	-0.03	0.62	0.99	0.04	-0.22	0.49	0.56	0.09	0.02	0.49	-0.08	0.3	0.52	0.08	0.17	0.02	0.16	0.2	0.2	0.22
Net Debt	-0.24		0.13	0.14	-0.19	-0.35	-0.45	0.16	-0.31	-0.1	0.15	-0.61	0.08	-0.47	0.17	0.41	-0.4	-0.43	-0.2	-0.61	-0.75	-0.58
Net Receivables	-0.03	0.13		0.07	-0.12	-0.11	-0.62	-0.27	-0.02	0.54	0.22	0.14	0.13	-0.21	0.06	0.54	-0.57	-0.19	-0.1	-0.59	-0.29	-0.45
Total Liab	0.62	0.14	0.07		0.59	-0.72	-0.24	0.32	0.49	0.31	-0.29	0.31	0.34	-0.49	0.65	-0.14	-0.05	0.25	-0.46	0.18	-0.07	0.14
Total Current Assets	0.99	-0.19	-0.12	0.59		0.07	-0.19	0.49	0.57	-0.03	0.03	0.37	-0.1	0.32	0.57	0.09	0.16	0.03	0.17	0.22	0.22	0.25
Total Stockholder Equity	0.04	-0.35	-0.11	-0.72	0.07		0.03	0.04	-0.13	-0.33	0.45	0.0	-0.52	0.85	-0.32	0.24	0.18	-0.34	0.82	-0.12	0.24	-0.07
Retained Earnings	-0.22	-0.45	-0.62	-0.24	-0.19	0.03		-0.03	-0.04	-0.3	-0.57	0.07	-0.26	0.08	-0.17	-0.86	0.72	0.6	-0.13	0.76	0.55	0.72
Short Term Debt	0.49	0.16	-0.27	0.32	0.49	0.04	-0.03		0.07	0.04	0.07	0.25	-0.29	0.09	-0.03	-0.04	0.35	-0.31	0.28	-0.03	-0.24	-0.02
Common Stock	0.56	-0.31	-0.02	0.49	0.57	-0.13	-0.04	0.07		0.16	-0.36	0.28	0.17	0.06	0.38	-0.17	-0.08	0.43	-0.06	0.47	0.51	0.64
Accounts Payable	0.09	-0.1	0.54	0.31	-0.03	-0.33	-0.3	0.04	0.16		0.08	0.61	0.35	-0.13	-0.2	0.08	-0.15	-0.12	-0.14	-0.06	-0.2	-0.14
Short Term Investments	0.02	0.15	0.22	-0.29	0.03	0.45	-0.57	0.07	-0.36	0.08		-0.07	-0.22	0.34	-0.25	0.68	-0.27	-0.76	0.53	-0.48	-0.33	-0.65
Property Plant Equipment	0.49	-0.61	0.14	0.31	0.37	0.0	0.07	0.25	0.28	0.61	-0.07		-0.11	0.27	-0.15	-0.25	0.48	0.03	0.16	0.3	0.21	0.25
Current Deferred Revenue	-0.08	0.08	0.13	0.34	-0.1	-0.52	-0.26	-0.29	0.17	0.35	-0.22	-0.11		-0.43	0.19	0.14	-0.58	0.19	-0.45	-0.02	-0.09	-0.06
Net Tangible Assets	0.3	-0.47	-0.21	-0.49	0.32	0.85	0.08	0.09	0.06	-0.13	0.34	0.27	-0.43		-0.26	0.13	0.31	-0.26	0.61	0.12	0.29	0.08
Long Term Debt	0.52	0.17	0.06	0.65	0.57	-0.32	-0.17	-0.03	0.38	-0.2	-0.25	-0.15	0.19	-0.26		-0.04	-0.16	0.38	-0.28	0.14	0.21	0.15
Capital Surpluse	0.08	0.41	0.54	-0.14	0.09	0.24	-0.86	-0.04	-0.17	0.08	0.68	-0.25	0.14	0.13	-0.04		-0.69	-0.7	0.27	-0.8	-0.51	-0.72
Short Long Term Debt	0.17	-0.4	-0.57	-0.05	0.16	0.18	0.72	0.35	-0.08	-0.15	-0.27	0.48	-0.58	0.31	-0.16	-0.69		0.14	0.23	0.56	0.3	0.49
Long Term Debt Total	0.02	-0.43	-0.19	0.25	0.03	-0.34	0.6	-0.31	0.43	-0.12	-0.76	0.03	0.19	-0.26	0.38	-0.7	0.14		-0.53	0.72	0.71	0.73
Net Invested Capital	0.16	-0.2	-0.1	-0.46	0.17	0.82	-0.13	0.28	-0.06	-0.14	0.53	0.16	-0.45	0.61	-0.28	0.27	0.23	-0.53		-0.17	0.1	-0.12
Cash And Equivalents	0.2	-0.61	-0.59	0.18	0.22	-0.12	0.76	-0.03	0.47	-0.06	-0.48	0.3	-0.02	0.12	0.14	-0.8	0.56	0.72	-0.17		0.8	0.89
Net Working Capital	0.2	-0.75	-0.29	-0.07	0.22	0.24	0.55	-0.24	0.51	-0.2	-0.33	0.21	-0.09	0.29	0.21	-0.51	0.3	0.71	0.1	0.8		0.8
Capital Stock	0.22	-0.58	-0.45	0.14	0.25	-0.07	0.72	-0.02	0.64	-0.14	-0.65	0.25	-0.06	0.08	0.15	-0.72	0.49	0.73	-0.12	0.89	0.8

Click cells to compare fundamentals

About Protalix Biotherapeutics Financial Statements

Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Capital Stock	73 K	49.5 K
Issuance Of Capital Stock	24 M	24.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protalix Capital Stock from 2010 to 2024

Latest Protalix Biotherapeutics' Capital Stock Growth Pattern

Protalix Capital Stock Regression Statistics

Protalix Capital Stock History

Other Fundumenentals of Protalix Biotherapeutics

Protalix Biotherapeutics Capital Stock component correlations

About Protalix Biotherapeutics Financial Statements

Also Currently Popular

Additional Tools for Protalix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY